Chemomab Therapeutics Ltd. Form SCHEDULE 13D — Nov 10, 2026
Scipher Medicine Corporation filed a Schedule 13D disclosing beneficial ownership of 74,576,240 Chemomab Therapeutics ordinary shares (10.4% of the class), representing 932,203 ADSs purchased on November 3, 2026 at $1.18 per ADS for approximately $1.1 million via Chemomab's ATM facility. The purchase was funded with $1.1 million of new senior unsecured convertible notes issued under Amendment No. 3 to Scipher's Convertible Note Purchase and Investment Obligation Agreement, with subscribers including Khosla Ventures VI, Northpond Capital, and Blue Owl Healthcare Opportunities funds, plus roughly $241,000 of Scipher working capital.
Key figures
- Deal Value Usd
- 1100000
- Offering Price
- 1.18
- Shares Outstanding
- 643889200
- Ads purchased
- 932203
- Note maturity
- August 5, 2027
- Percent of class
- 10.4%
- Note interest rate
- 10% per annum (13% after maturity)
- Expected merger close
- first calendar quarter of 2027
- Company atm investment
- 989615
- Notes principal amount
- 1100000
- Beneficially owned ordinary shares
- 74576240
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.